An experimental oral drug that partially blocks a brain enzyme tied to learning and memory. Caregivers rated men with an inherited intellectual disability better on drug than placebo; direct memory and vocabulary tests failed in larger studies. In healthy older adults only low doses helped, a higher dose went with worse performance. Unapproved; supply outside trials is laboratory chemical. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight | Within 2% of personal baseline | Class-wide weight loss with sustained PDE4 inhibition |
| ALT and AST | ALT below 25 U/L (men), below 20 U/L (women) | Liver strain from an unapproved, hepatically cleared compound |
| Creatinine and eGFR | eGFR above 90 mL/min/1.73 m² | Reduced kidney filtering raises drug exposure |
| Creatine kinase | Below 150 U/L | Muscle breakdown occurred once on drug, and transporter inhibition may raise statin levels |
| Fasting lipid panel with LDL cholesterol | LDL cholesterol below 70 mg/dL when taking a statin | Detects changed statin exposure from the transporter interaction |
| Complete blood count | Within conventional reference range | General safety screen for a compound with no published long-term record |
| PHQ-9 and GAD-7 scores | Both below 5 | The psychiatric class signal, including suicidal ideation |
| Computerized cognitive battery | No established target exists; track change from the individual's own baseline | Both the claimed benefit and the documented dose-dependent harm |
Cadence: Full baseline before the first dose, with the cognitive battery run at least twice. Thereafter mood questionnaires and cognitive testing every four weeks, weight weekly, and bloodwork at six weeks, three months, and then every six months.